Clinical Trial: IAT-MeVO Trial Domain Within the ACT-GLOBAL Adaptive Platform Trial

U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07336927) titled 'IAT-MeVO Trial Domain Within the ACT-GLOBAL Adaptive Platform Trial' on Jan. 04.

Brief Summary: IAT-MeVO is an international, multicenter, prospective, randomised, open-label, blinded end-point assessed (PROBE) trial, to evaluate the efficacy and safety of endovascular therapy (EVT) [intra-arterial thrombolysis (IAT)-based] versus best medical management (BMT) in patients with acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) who are ineligible for intravenous thrombolysis (IV) within 24 h of onset.

Study Start Date: Jan. 01

Study Type: INTERVENTIONAL

Condition: Acute Ischemic Stroke Due to Medium-vessel-occlusio...